AgeX Therapeutics Publishes Data in Peer-Reviewed Journal to Advance Potential Cell Therapy AgeX-BAT1 for Type II Diabetes & ...
January 09 2019 - 8:00AM
Business Wire
- 30M U.S. adults suffer from diabetes
and 93M from obesity, with associated medical costs of over $300B
annually, necessitating an urgent need for novel treatments
- AgeX-BAT1 for Type II diabetes and
obesity aims to return brown adipose tissue, also known as “brown”
or “good” fat, back to levels found in young adults
- Loss of brown fat as a result of aging
is associated with obesity and Type II diabetes as well as
heightened cardiovascular risk
- Published data shows that AgeX’s
pioneering PureStem® cell therapy manufacturing platform generated
highly pure, identifiable and scalable brown adipose cells,
expressing active adipokines such as adiponectin
AgeX Therapeutics, Inc. (NYSE American: AGE) announced today the
publication of data relating to its cell therapy product candidate
AgeX-BAT1 for Type II diabetes and obesity in the peer-reviewed
scientific journal Stem Cell Research & Therapy. Scientists now
realize that the activity of brown adipose tissue (BAT), also known
as “brown” or “good” fat, is markedly lost with age. This loss may
contribute to metabolic disturbances seen in Type II diabetes and
obesity as well as a heightened cardiovascular risk. AgeX-BAT1 is
comprised of regenerative cells capable of becoming BAT and is
intended to return BAT levels back to those found in young adults.
AgeX is targeting Type II diabetes and obesity as they are areas of
high unmet medical need and present multi-billion-dollar market
opportunities.
As described in the paper, “Clonal Derivation of White and Brown
Adipocyte Progenitor Cell Lines from Human Pluripotent Stem Cells,”
two AgeX-BAT1 cell lines, designated NP88 and NP110, were selected
for detailed characterization. The data demonstrate AgeX’s
PureStem® cell therapy manufacturing platform was successful in
generating highly purified cells with precise anatomical identity,
and most importantly, capable of potently expressing definitive
markers of BAT cells, including active adipokines such as
adiponectin. Adiponectin is reported to have beneficial effects in
patients with age-related metabolic and cardiovascular diseases. In
addition, the paper provides evidence that AgeX’s PureStem®
technology allows for the reliable re-derivation of scalable lots
of desired cells.
“In keeping with AgeX’s mandate to use regenerative biology to
reverse the degenerative aspects of aging, AgeX-BAT1 will address
one of the insidious age-related metabolic imbalances responsible
for age-related weight gain as well as other serious age-related
conditions such as Type II diabetes and its ensuing cardiovascular
risk,” said Michael D. West, Ph.D., Founder and CEO of AgeX, and
lead author of the published study. “It is estimated that 30
million U.S. adults have diabetes, the overwhelming majority of the
cases being Type II, and that number is rapidly on the rise as a
result of the aging demographic. AgeX-BAT1 could potentially
provide an important and novel therapeutic strategy for managing
the epidemic of metabolic imbalances such as Type II diabetes in
aging.”
"Few medical conditions are as prevalent as age-related
metabolic imbalances, which carry along with them serious risks,
including diabetes, cardiovascular disease, blindness, amputations,
and cancer,” said Dr. Annalisa Jenkins, M.B.B.S., F.R.C.P., a
member of the AgeX Board of Directors. "Whilst dieting and exercise
are beneficial, most people find them difficult to adhere to. To
meet this high unmet medical need, we need new approaches, such as
AgeX-BAT1.”
Dr. West will discuss the paper as part of his presentation at
Biotech Showcase, being held concurrently with the 2019 J.P. Morgan
Healthcare Conference in San Francisco. Details of Dr. West’s
presentation follow:
Date: Wednesday, January 9Time: 9:00AM
PSTTrack: Yosemite-A (Ballroom
Level)Venue: Hilton San Francisco Union Square, 333
O’Farrell Street, San Francisco, Calif.
Authors on the paper are Michael West, Dana Larocca, Jie Li,
Jianjie Jiang, Pamela Sim, Ivan Labat, and Hal Sternberg of AgeX;
Ching-Fang Chang and Andreas Stahl of the University of California,
Berkeley; Karen B. Chapman of Johns Hopkins University; Kari E.
Wong of Metabolon, Inc.; James Nicoll and Michael J. Van Kanegan of
Zen-BIO, Inc.; Aubrey de Grey of AgeX and the SENS Research
Foundation; and Igor Nasonkin of BioTime, Inc.
The paper is available online, and additional information on
AgeX-BAT1, including an introductory video, is available on AgeX’s
website at www.agexinc.com.
About AgeX-BAT1
The activity of brown adipose tissue (BAT), or “brown fat”, is
abundant early in life, but is lost precipitously with age. This
tissue is believed to generate heat using blood glucose and
circulating fat. The abundance of this tissue in the young is
believed to keep metabolism in balance. Its loss with age is
understood to lead to weight gain, central obesity, accumulation of
fat in the coronary arteries, and Type II diabetes.
The demonstration that the transplantation of BAT from young
mice to obese diabetic mice results in improvements in both weight
and insulin sensitivity has led to a search for a source of
industrially-scalable clinical grade BAT cells to recreate youthful
levels of the tissue in old age.
AgeX plans to use HyStem® as a matrix to support the engraftment
of AgeX-BAT1 cells. HyStem® is a matrix previously used in clinical
trials by BioTime, Inc. for lipotransfer.
About AgeX Therapeutics
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on
developing and commercializing innovative therapeutics for human
aging. Its PureStem® and UniverCyte™ manufacturing and
immunotolerance technologies are designed to work together to
generate highly defined, universal, allogeneic, off-the-shelf
pluripotent stem cell-derived young cells of any type for
application in a whole host of diseases with a high unmet medical
need. AgeX has two preclinical cell therapy programs: AGEX-VASC1
(vascular progenitor cells) for tissue ischemia and AGEX-BAT1
(brown fat cells) for Type II diabetes. AgeX’s revolutionary
longevity platform named induced Tissue Regeneration (iTR™) aims to
unlock cellular immortality and regenerative capacity to reverse
age-related changes within tissues. AGEX-iTR1547 is an iTR-based
formulation in preclinical development. HyStem® is AgeX’s delivery
technology to stably engraft PureStem cell therapies and slowly
release iTR molecules in the body. AgeX is aggressively developing
its core product pipeline for use in the clinic to extend human
healthspan, and is seeking opportunities to form licensing and
partnership agreements around its broad IP estate and proprietary
technology platforms for non-core clinical applications.
For more information, please visit www.agexinc.com or connect
with the company on Twitter, Facebook and YouTube.
Forward-Looking StatementsCertain statements contained in
this release are “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995. Any
statements that are not historical fact including, but not limited
to statements that contain words such as “will,” “believes,”
“plans,” “anticipates,” “expects,” “estimates” should also be
considered forward-looking statements. Forward-looking statements
involve risks and uncertainties. Actual results may differ
materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the business of AgeX Therapeutics, Inc.
and its subsidiaries, particularly those mentioned in the
cautionary statements found in more detail in the “Risk Factors”
section of AgeX’s Information Statement filed as an exhibit to its
Registration Statement on Form 10 with the Securities and Exchange
Commissions (copies of which may be obtained at www.sec.gov).
Subsequent events and developments may cause these forward-looking
statements to change. AgeX specifically disclaims any obligation or
intention to update or revise these forward-looking statements as a
result of changed events or circumstances that occur after the date
of this release, except as required by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190109005309/en/
for AgeX:Bill DouglassGotham Communications,
LLCbill@gothamcomm.com(646) 504-0890
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2023 to Apr 2024